Pediatrix Medical Group Inc. (MD) — RQD Stock Rating Cockpit

Per the Roarable RQD rating, MD scores 76 out of 100, grading B+ and labeled "Roarable Buy — Very Good Cash & Smart-Money Inflow." The five pillars are:

• Fundamental Cash Engine: 16 / 20. Per the RQD rating, this reflects ROIC of 33.6% and an FCF yield of 11.43%. For an investor, these are the strongest quantitative supports in the rating: capital appears to generate high returns, and free cash flow is large relative to the market value.
• Whale 13F Flow: 16 / 20. Per the RQD rating, this pillar captures institutional accumulation and options positioning. Positive institutional flow can support the price, but the underlying holder detail is not provided in this dataset.
• Insider Conviction: 17 / 20. Per the RQD rating, this is the highest pillar and reflects SEC Form 4 and Congressional PTR cluster flow. Strong insider signaling is a notable upside driver, though the individual transactions are not itemized in the source data.
• Macro Regime Fit: 14 / 20. Per the RQD rating, beta is 1.0 with sector sensitivity. For an investor, this means MD is expected to move roughly in line with the broad market, so macro-driven drawdowns are not structurally amplified, but sector-specific shocks remain a factor.
• Forensic Balance Sheet: 13 / 20. Per the RQD rating, Altman Z is 2.5, Piotroski F is 6/9, and Debt/Equity is 0.5. This is the lowest pillar, indicating a solid but less pristine balance sheet than the cash and insider pillars suggest.

Valuation tradeoff: per the market data, trailing P/E is 14.3 and forward P/E is 13.3, with EV/EBITDA of 9.6. A prospective investor should weigh the strong cash-flow and insider signals against a valuation that is not stretched on these measures but has already moved meaningfully, as the news wire references a 154% run. The primary upside driver is sustained cash generation and insider conviction; the primary risk is that a balance sheet rated 13/20 offers less cushion if operating conditions weaken.

Pediatrix Medical Group Inc. is a NYSE-listed issuer in the Health Care sector, operating in the Hospital/Nursing Management industry, per the company profile. The profile identifies the business as a hospital and nursing management operator. Customer base, service lines, and revenue model are not available in source data. Revenue is reported as $0.0M in each period of the financials, so the revenue-generation mechanics cannot be described from this dataset.

Per the SEC financials, operating income moved from negative in FY 2024 to $208.8M in FY 2025, and net income moved from $-99.1M to $165.4M over the same span. Free cash flow was positive in all three periods, rising from $137.3M to $271.1M. Per the market data, gross, operating, and net margins are each reported as 0%, so margin analysis cannot be performed from this dataset. Per the Roarable RQD rating, ROIC is 33.6%, Altman Z is 2.5, Piotroski F is 6/9, and Debt/Equity is 0.5, indicating a moderately healthy balance sheet posture.

Per the recent news and catalysts feed, six items cover MD:

• Green-light catalyst: a TradingView report headlined that Pediatrix Medical Group beats Q3 2026 sales expectations, flagged as a CATALYST with GREEN status.
• Yellow-light market wire items: Yahoo Finance and ChartMill coverage describes the stock as undervalued despite a large run and as a value stock trading at a discount with solid profitability. A Yahoo Finance piece covers what management said on its Q3 earnings call. Simply Wall St reports the stock is back in focus. Stock Titan reports revenue rose 1.7% while net income fell to $47 million.
• Risk watch item: the Stock Titan headline notes net income declined to $47 million despite revenue growth, which is a margin-quality question to monitor.
• Proprietary signals: the Butterfly Supply-Chain Graph reports no proprietary signals and no supply-chain links.

The feed is largely headline-level; the full content of the earnings call and sales beat is not available in source data.

Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, with no butterfly links. Upstream dependencies, downstream customers, and sector correlations beyond the Health Care sector classification are not available in source data. Second-order bottlenecks cannot be identified from this dataset. An investor should note that the absence of mapped links is itself a limitation rather than evidence of an absence of dependencies.

• Revenue is reported as $0.0M in every period. What is the actual top-line figure, and how do revenue and margins reconcile with the reported operating and net income?
• Net income in the Stock Titan headline is cited as $47 million, which differs from the $165.4M FY 2025 figure in the SEC financials. Which period and basis does each figure reflect?
• What drove the swing from a FY 2024 operating loss of $-68.7M to a FY 2025 operating income of $208.8M, and is it recurring?
• Which institutional and insider transactions make up the 16/20 whale and 17/20 insider pillar scores, and who are the principal holders?
• Debt is reported as N/A in every period, so what is the actual debt load behind the stated Debt/Equity of 0.5?